CNRI-Los Angeles, LLC

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Schizophrenia3 trials
• Depression1 trial

Phase

• Phase 33 trials
• Phase 21 trial

Status

• Completed2 trials
• Recruiting2 trials

Lead sponsor

• Karuna Therapeutics, Inc., a Bristol Myers Squibb company2 trials
• Intra-Cellular Therapies, Inc.1 trial
• Novartis Pharmaceuticals1 trial

Running trials

• Recruiting

  Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

  NCT07467993· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Mohamed El-Gabalawy (principal investigator)

• Recruiting

  Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

  NCT05850689· Phase 3· Intra-Cellular Therapies, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression1 recruiting
• Schizophrenia1 recruiting

Closed trials

• Completed

  A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05145413· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Completed

  An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

  NCT04820309· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source